ストックスクリーナーアプリを入手
3.18
12.37%
0.35
プレマーケット:
3.02
-0.16
-5.03%
前日終値:
$2.83
開ける：
$4.51
24時間の取引高:
54.44M
Relative Volume:
63.38
時価総額：
$13.48M
収益：
-
当期純損益:
$-21.79M
株価収益率:
-0.5142
EPS:
-6.1838
ネットキャッシュフロー:
$-23.12M
1週間 パフォーマンス:
+24.22%
1か月 パフォーマンス:
+24.71%
6か月 パフォーマンス:
-4.79%
1年 パフォーマンス:
+1,095%
1日の値動き範囲:
$3.11
$4.70
1週間の範囲:
$2.51
$4.70
52週間の値動き範囲:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
名前
Cellectar Biosciences Inc
セクター
電話
(608) 441-8120
住所
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.18 | 13.48M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | アップグレード | Maxim Group | Hold → Buy |
| 2024-12-05 | 再開されました | Ladenburg Thalmann | Buy |
| 2020-07-01 | 開始されました | Oppenheimer | Outperform |
| 2020-01-21 | 再開されました | ROTH Capital | Buy |
| 2019-09-13 | 開始されました | ROTH Capital | Buy |
| 2016-12-21 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus - TechStock²
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results - Benzinga
CLRB Stock Surges 28.6% on $140M Financing and Positive Trial Data - Meyka
Cellectar Biosciences announces up to $140M financing deal; shares surge - MSN
Dow Jumps Over 300 Points; Tyson Foods Posts Upbeat Earnings - Benzinga
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia - Investing News Network
Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia - Yahoo Finance
CLRB Stock Pops As New Cancer Trial Sparks Trading Interest - StocksToTrade
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses - Benzinga
Cellectar Biosciences raises up to $140 million in financing By Investing.com - Investing.com South Africa
CLRB Stock Jumps As New Breast Cancer Trial Begins - timothysykes.com
Cellectar reports 12-month data for WM treatment trial - Investing.com
Cellectar reports 12-month data for WM treatment trial By Investing.com - Investing.com Canada
Cancer drug posts 17.8-month responses after four 30-minute infusions - Stock Titan
Cellectar Biosciences Inc. (CLRB) has successfully completed a financing round, led by Nantahala Capital Management, LLC. - Bitget
Cellectar Biosciences raises up to $140 million in financing - Investing.com
Cellectar Biosciences stock soars 130% on $140M financing By Investing.com - Investing.com Australia
Cellectar Biosciences Reports Positive 12-Month Follow-Up - GlobeNewswire
Cellectar Biosciences stock soars 130% on $140M financing - Investing.com
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million - The Manila Times
Cellectar lines up $140M to fund cancer drug study and FDA filing - Stock Titan
MSN - MSN
Cellectar Biosciences (CLRB) price target decreased by 59.62% to 14.28 - MSN
MSN Money - MSN
Cellectar Biosciences (NASDAQ: CLRB) details governance, ownership and financings in 10-K/A - Stock Titan
CLRB Price Today: Cellectar Biosciences INC NEW Stock Price, Quote & Chart | MEXC - MEXC Exchange
CLRB (Cellectar Biosciences Inc.) reports narrower than expected Q4 2025 loss, yet shares drop nearly 3 percent.High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Cellectar to present WM treatment data at oncology meeting By Investing.com - Investing.com Australia
Cellectar to present WM treatment data at oncology meeting - Investing.com
Cellectar Biosciences, Inc. Announces Acceptance of Abstract for Presentation on Iopofosine I-131 at ASCO Annual Meeting - Quiver Quantitative
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 - marketscreener.com
Cellectar takes cancer-drug data to ASCO for patients with no approved therapy - Stock Titan
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences (CLRB) Begins Phase 1b Trial for Triple Ne - GuruFocus
Cellectar enrolls first patient in phase 1b cancer trial By Investing.com - Investing.com South Africa
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Triple Negative Breast Cancer - National Today
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer - National Today
Cellectar enrolls first patient in phase 1b cancer trial - Investing.com
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) - The Manila Times
First patient joins Cellectar study for hard-to-treat breast cancer - Stock Titan
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer - Intellectia AI
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Aug Mood: Can Cellectar Biosciences Inc weather a recession2026 PostEarnings & Entry Point Strategy Guides - baoquankhu1.vn
CEO Moves: Is Cellectar Biosciences Inc a top pick in the sectorIPO Watch & Weekly Top Performers Watchlists - baoquankhu1.vn
Growth Value: Will Cellectar Biosciences Inc stock benefit from M AQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Trading Action: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Buybacks Report: How does Cellectar Biosciences Inc compare to its peersQuarterly Portfolio Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
Is Cellectar (CLRB) Stock Cheap at Current Price | Price at $2.68, Up 5.10%Asset Allocation - Xã Thanh Hà
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Aug Technicals: Will Cellectar Biosciences Inc outperform during market ralliesOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Smart Money: Is Cellectar Biosciences Inc a top pick in the sectorQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Cellectar Biosciences Inc (CLRB) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):